聚乙二醇干扰素α-2b治疗慢性乙型肝炎的疗效  

Efficacy of pegylated interferon α-2b in treatment of chronic hepatitis B

作　　者：董格峰[1] 孙玉秋[1] 李程[1] 解双双[1] 

机构地区：[1]山东大学附属济南市传染病医院肝病科,山东省济南市250021

出　　处：《世界华人消化杂志》2014年第11期1569-1573,共5页World Chinese Journal of Digestology

摘　　要：目的:探讨聚乙二醇干扰素α-2b(paginated interferonα-2b,PEG-IFNα-2b)在治疗慢性乙型肝炎(chronic hepatitis B,CHB)的疗效.方法:选择2012-06/2013-06入院接受治疗的CHB患者60例,对其使用PEG-IFNα-2b进行治疗,观察患者用药前后肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、γ干扰素(interferon-γ,IFN-γ)、白介素-6(interleukin-6,I L-6)、I L-8和I L-10变化,并分析治疗后3、6、9 mo不同阶段时患者HBeAg/HBeAb与HBV DNA水平变化.结果:患者在接受治疗后的各个阶段内TNF-α、IFN-γ、IL-6、IL-8和IL-10均出现变化,且数据的比较差异有统计学意义(P<0.05);患者接受治疗3 mo后丙氨酸转氨酶(alanine aminotransferase,ALT)复常患者有11例,复常率为18.33%、HBeAg转阴患者7例,转阴率11.66%、HBeAg转阴患者15例,转阴率为25.00%.患者接受治疗6 mo后ALT复常患者有32例,复常率为53.33%、HBeAg转阴患者20例,转阴率33.33%、HBeAg转阴患者26例,转阴率为43.33%.患者接受治疗9 mo后ALT复常患者有46例,复常率为76.6%、HBeAg转阴患者37例,转阴率61.6%、HBeAg转阴患者37例,转阴率为61.6%.患者接受治疗3、6、9 mo后肝功能恢复率、HBeAg转阴率和HBV-DNA转阴率均存在明显差异,具有统计学意义(P<0.05).结论:PEG-IFNα-2b治疗CHB具有一定的临床意义,值得在临床上推广使用.AIM： To investigate the efficacy of pegylated interferon α-2b （PEG-IFN α-2b） in the treatment of chronic hepatitis B （CHB）. METHODS： Sixty hospitalized patients with CHB who were treated with PEG-IFN α-2b from June 2012 to June 2013 were included in this study. Changes in tumor necrosis factor-α （TNF-α）, γ interferon （IFN-γ）, interleukin-6 （IL-6）, IL-8 and IL-10 were observed between before and after treatment. HBeAg/HBeAb status and HBV DNA levels were detected 3, 6 and 9 mo after treatment. RESULTS： After treatment, TNF-α, IFN-γ, IL-6, IL-8 and IL-10 showed significant changes compared with pretreatment data （P 〈 0.05）. Three months after treatment, ALT normalization was achieved in 11 （18.33%） cases, negative conversion of HBeAg in 7 （11.66%） cases, and negative conversion of HBV DNA in 15 （25.00%） cases. Six months after treatment, ALT normalization was achieved in 32 （53.33%） cases, negative conversion of HBeAg in 20 （33.33%） cases, and negative conversion of HBV DNA in 26 （43.33%） cases. Nine months after treatment, ALT normalization was achieved in 46 （76.6%） cases, negative conversion of HBeAg in 37 （61.6%） cases, and negative conversion of HBV DNA in 37 （61.6%） cases. The rates of liver function recovery, HBeAg seroconversion and negative conversion of HBV DNA were significantly different between before and 3, 6 and 9 mo after treatment （P 〈 0.05）. CONCLUSION： PEG-IFN α-2b is effective in the treatment of CHB.

关 键 词：聚乙二醇干扰素 慢性乙型肝炎 临床疗效 

分 类 号：R512.62[医药卫生—内科学]